{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T09:27:31Z","timestamp":1769246851287,"version":"3.49.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Millennium Pharmaceuticals Inc.","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n                <jats:title>Abstract<\/jats:title>\n                <jats:p>Autologous stem cell transplantation (ASCT) is a well-established approach to treatment of patients with relapsed\/refractory (R\/R) Hodgkin lymphoma (HL) recommended by both the European Society for Medical Oncology and the National Comprehensive Cancer Network based on the results from randomized controlled studies. However, a considerable number of patients who receive ASCT will progress\/relapse and display suboptimal post-transplant outcomes. Over recent years, a number of different strategies have been assessed to improve post-ASCT outcomes and augment HL cure rates. These include use of pre- and post-ASCT salvage therapies and post-ASCT consolidative therapy, with the greatest benefits demonstrated by targeted therapies, such as brentuximab vedotin. However, adoption of these new approaches has been inconsistent across different centers and regions.<\/jats:p>\n                <jats:p>In this article, we provide a European perspective on the available treatment options and likely future developments in the salvage and consolidation settings, with the aim to improve management of patients with HL who have a high risk of post-ASCT failure.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We conclude that early intervention with post-ASCT consolidation improves outcomes in patients with R\/R HL who require ASCT. Future approvals of targeted agents are expected to further improve outcomes and provide additional treatment options in the coming age of personalized medicine.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-020-07561-2","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T17:04:14Z","timestamp":1605027854000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Improving outcomes after autologous transplantation in relapsed\/refractory Hodgkin lymphoma: a European expert perspective"],"prefix":"10.1186","volume":"20","author":[{"given":"Anna","family":"Sureda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria G.","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Gisselbrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodoros P.","family":"Vassilakopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Walewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,10]]},"reference":[{"key":"7561_CR1","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1182\/blood-2017-09-772640","volume":"131","author":"SH Lim","year":"2018","unstructured":"Lim SH, Johnson PWM. Optimizing therapy in advanced-stage Hodgkin lymphoma. Blood. 2018;131:1679\u201388.","journal-title":"Blood."},{"key":"7561_CR2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3322\/caac.21438","volume":"68","author":"S Shanbhag","year":"2018","unstructured":"Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018;68:116\u201332.","journal-title":"CA Cancer J Clin"},{"key":"7561_CR3","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMra1003733","volume":"363","author":"JO Armitage","year":"2010","unstructured":"Armitage JO. Early-stage Hodgkin\u2019s lymphoma. N Engl J Med. 2010;363:653\u201362.","journal-title":"N Engl J Med"},{"key":"7561_CR4","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3816\/CLM.2009.n.034","volume":"9","author":"E Iannitto","year":"2009","unstructured":"Iannitto E, Minardi V, Gobbi PG, Calvaruso G, Tripodo C, Marcheselli L, et al. Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial. Clin Lymphoma Myeloma. 2009;9:138\u201344.","journal-title":"Clin Lymphoma Myeloma"},{"key":"7561_CR5","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2015.62.4817","volume":"34","author":"F Merli","year":"2016","unstructured":"Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, et al. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol. 2016;34:1175\u201381.","journal-title":"J Clin Oncol"},{"key":"7561_CR6","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","volume":"390","author":"P Borchmann","year":"2018","unstructured":"Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, et al. PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2018;390:2790\u2013802.","journal-title":"Lancet."},{"key":"7561_CR7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","volume":"20","author":"RO Casasnovas","year":"2019","unstructured":"Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2019;20:202\u201315.","journal-title":"Lancet Oncol"},{"key":"7561_CR8","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1995;333:1540\u20135.","journal-title":"N Engl J Med"},{"key":"7561_CR9","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet. 2002;359:2065\u201371.","journal-title":"Lancet."},{"key":"7561_CR10","volume-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae) for Hodgkin lymphoma V.2.2019","author":"NCCN","year":"2019","unstructured":"NCCN (2019). NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae) for Hodgkin lymphoma V.2.2019. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hodgkins.pdf. Accessed 1 Oct 2019."},{"key":"7561_CR11","doi-asserted-by":"crossref","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","volume":"29","author":"DA Eichenauer","year":"2018","unstructured":"Eichenauer DA, Aleman BMP, Andre M, Federico M, Hutchings M, Illidge T, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv19\u201329.","journal-title":"Ann Oncol"},{"key":"7561_CR12","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/bjh.16201","volume":"188","author":"P Kaloyannidis","year":"2019","unstructured":"Kaloyannidis P, Hertzberg M, Webb K, Zomas A, Schrover R, Hurst M, et al. Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation. Br J Haematol. 2019;188:540\u20139.","journal-title":"Br J Haematol"},{"key":"7561_CR13","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/sj.bmt.1704214","volume":"32","author":"T Kewalramani","year":"2003","unstructured":"Kewalramani T, Nimer SD, Zelenetz AD, Malhotra S, Qin J, Yahalom J, et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin\u2019s disease or aggressive non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant. 2003;32:673\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"7561_CR14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.bmt.1701325","volume":"22","author":"JE Lancet","year":"1998","unstructured":"Lancet JE, Rapoport AP, Brasacchio R, Eberly S, Raubertas RF, Linder T, et al. Autotransplantation for relapsed or refractory Hodgkin\u2019s disease: long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant. 1998;22:265\u201371.","journal-title":"Bone Marrow Transplant"},{"key":"7561_CR15","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.1999.17.10.3101","volume":"17","author":"JW Sweetenham","year":"1999","unstructured":"Sweetenham JW, Carella AM, Taghipour G, Cunningham D, Marcus R, Della Volpe A, et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin\u2019s disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol. 1999;17:3101\u20139.","journal-title":"J Clin Oncol"},{"key":"7561_CR16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","volume":"16","author":"AJ Moskowitz","year":"2015","unstructured":"Moskowitz AJ, Schoder H, Yahalom J, Mccall SJ, Fox SY, Gerecitano J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16:284\u201392.","journal-title":"Lancet Oncol"},{"key":"7561_CR17","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","volume":"132","author":"CH Moskowitz","year":"2018","unstructured":"Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132:2639\u201342.","journal-title":"Blood."},{"key":"7561_CR18","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","volume":"341","author":"DC Linch","year":"1993","unstructured":"Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, Mcmillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341:1051\u20134.","journal-title":"Lancet."},{"key":"7561_CR19","doi-asserted-by":"crossref","unstructured":"Rancea M, Monsef I, Von Tresckow B, Engert A, Skoetz N. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed\/refractory Hodgkin lymphoma. Cochrane Database Syst Rev. 2013;(6):Cd009411.","DOI":"10.1002\/14651858.CD009411.pub2"},{"key":"7561_CR20","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/annonc\/mdf221","volume":"13","author":"A Josting","year":"2002","unstructured":"Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, et al. Time-intensified dexamethasone\/cisplatin\/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin\u2019s disease. Ann Oncol. 2002;13:1628\u201335.","journal-title":"Ann Oncol"},{"key":"7561_CR21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/annonc\/mdi003","volume":"16","author":"A Josting","year":"2005","unstructured":"Josting A, Rudolph C, Mapara M, Glossmann JP, Sieniawski M, Sieber M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol. 2005;16:116\u201323.","journal-title":"Ann Oncol"},{"key":"7561_CR22","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1182\/blood.V93.11.3632","volume":"93","author":"J Rodriguez","year":"1999","unstructured":"Rodriguez J, Rodriguez MA, Fayad L, Mclaughlin P, Swan F, Sarris A, et al. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin\u2019s disease. Blood. 1999;93:3632\u20136.","journal-title":"Blood."},{"key":"7561_CR23","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1023\/A:1026454831340","volume":"10","author":"J Aparicio","year":"1999","unstructured":"Aparicio J, Segura A, Garcera S, Oltra A, Santaballa A, Yuste A, et al. ESHAP is an active regimen for relapsing Hodgkin\u2019s disease. Ann Oncol. 1999;10:593\u20135.","journal-title":"Ann Oncol"},{"key":"7561_CR24","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00277-014-2114-0","volume":"93","author":"J Labrador","year":"2014","unstructured":"Labrador J, Cabrero-Calvo M, Perez-Lopez E, Mateos MV, Vazquez L, Caballero MD, et al. ESHAP as salvage therapy for relapsed or refractory Hodgkin\u2019s lymphoma. Ann Hematol. 2014;93:1745\u201353.","journal-title":"Ann Hematol"},{"key":"7561_CR25","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/oxfordjournals.annonc.a059242","volume":"6","author":"C Ferme","year":"1995","unstructured":"Ferme C, Bastion Y, Lepage E, Berger F, Brice P, Morel P, et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin\u2019s disease. Ann Oncol. 1995;6:543\u20139.","journal-title":"Ann Oncol"},{"key":"7561_CR26","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","volume":"97","author":"CH Moskowitz","year":"2001","unstructured":"Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97:616\u201323.","journal-title":"Blood."},{"key":"7561_CR27","doi-asserted-by":"crossref","unstructured":"Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin\u2019s and Hodgkin\u2019s lymphoma. Ann Oncol. 2006;17(Suppl 4):iv25\u201330.","DOI":"10.1093\/annonc\/mdj995"},{"key":"7561_CR28","doi-asserted-by":"crossref","unstructured":"Proctor SJ, Jackson GH, Lennard A, Angus B, Wood K, Lucraft HL, et al. Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK). Ann Oncol. 2003;14(Suppl 1):i47\u201350.","DOI":"10.1093\/annonc\/mdg710"},{"key":"7561_CR29","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2141.2011.08594.x","volume":"153","author":"D Sibon","year":"2011","unstructured":"Sibon D, Ertault M, Al Nawakil C, De Bazelaire C, Franchi P, Briere J, et al. Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD\/EBVP: a prospective monocentre study on 34 patients. Br J Haematol. 2011;153:191\u20138.","journal-title":"Br J Haematol"},{"key":"7561_CR30","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","volume":"18","author":"NL Bartlett","year":"2007","unstructured":"Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, Van Besien K, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin\u2019s lymphoma: CALGB 59804. Ann Oncol. 2007;18:1071\u20139.","journal-title":"Ann Oncol"},{"key":"7561_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3324\/haematol.10661","volume":"92","author":"A Santoro","year":"2007","unstructured":"Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma. Haematologica. 2007;92:35\u201341.","journal-title":"Haematologica."},{"key":"7561_CR32","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/annonc\/mdg496","volume":"14","author":"T Baetz","year":"2003","unstructured":"Baetz T, Belch A, Couban S, Imrie K, Yau J, Myers R, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin\u2019s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 2003;14:1762\u20137.","journal-title":"Ann Oncol"},{"key":"7561_CR33","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.2147\/OTT.S70264","volume":"7","author":"A Gutierrez","year":"2014","unstructured":"Gutierrez A, Rodriguez J, Martinez-Serra J, Gines J, Paredes P, Garcia F, et al. Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma. Oncol Targets Ther. 2014;7:2093\u2013100.","journal-title":"Oncol Targets Ther"},{"key":"7561_CR34","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1200\/JCO.2016.66.4466","volume":"34","author":"A Santoro","year":"2016","unstructured":"Santoro A, Mazza R, Pulsoni A, Re A, Bonfichi M, Zilioli VR, et al. Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase II study. J Clin Oncol. 2016;34:3293\u20139.","journal-title":"J Clin Oncol"},{"key":"7561_CR35","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","volume":"119","author":"CH Moskowitz","year":"2012","unstructured":"Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012;119:1665\u201370.","journal-title":"Blood."},{"key":"7561_CR36","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jamaoncol.2018.6278","volume":"5","author":"AS Kanate","year":"2019","unstructured":"Kanate AS, Kumar A, Dreger P, Dreyling M, Le Gouill S, Corradini P, et al. Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation: a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. JAMA Oncol. 2019;5:715\u201322.","journal-title":"JAMA Oncol"},{"key":"7561_CR37","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/j.1365-2141.2003.04828.x","volume":"124","author":"CH Moskowitz","year":"2004","unstructured":"Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin\u2019s disease. Br J Haematol. 2004;124:645\u201352.","journal-title":"Br J Haematol"},{"key":"7561_CR38","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/annonc\/mdn052","volume":"19","author":"B Sirohi","year":"2008","unstructured":"Sirohi B, Cunningham D, Powles R, Murphy F, Arkenau T, Norman A, et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin\u2019s lymphoma. Ann Oncol. 2008;19:1312\u20139.","journal-title":"Ann Oncol"},{"key":"7561_CR39","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1182\/asheducation-2016.1.331","volume":"2016","author":"C Moskowitz","year":"2016","unstructured":"Moskowitz C. Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2016;2016:331\u20138.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"7561_CR40","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2010.30.5771","volume":"28","author":"A Josting","year":"2010","unstructured":"Josting A, Muller H, Borchmann P, Baars JW, Metzner B, Dohner H, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin\u2019s lymphoma. J Clin Oncol. 2010;28:5074\u201380.","journal-title":"J Clin Oncol"},{"key":"7561_CR41","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","volume":"31","author":"AJ Moskowitz","year":"2013","unstructured":"Moskowitz AJ, Hamlin PA Jr, Perales MA, Gerecitano J, Horwitz SM, Matasar MJ, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2013;31:456\u201360.","journal-title":"J Clin Oncol"},{"key":"7561_CR42","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/bjh.12548","volume":"163","author":"PL Zinzani","year":"2013","unstructured":"Zinzani PL, Derenzini E, Pellegrini C, Celli M, Broccoli A, Argnani L. Bendamustine efficacy in Hodgkin lymphoma patients relapsed\/refractory to brentuximab vedotin. Br J Haematol. 2013;163:681\u20133.","journal-title":"Br J Haematol"},{"key":"7561_CR43","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/bjh.12821","volume":"166","author":"A Anastasia","year":"2014","unstructured":"Anastasia A, Carlo-Stella C, Corradini P, Salvi F, Rusconi C, Pulsoni A, et al. Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi. Br J Haematol. 2014;166:140\u20132.","journal-title":"Br J Haematol"},{"key":"7561_CR44","volume-title":"(Adcetris) summary of product characteristics","author":"Takeda Pharmaceuticals","year":"2018","unstructured":"Takeda Pharmaceuticals. (Adcetris) summary of product characteristics. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/adcetris-epar-product-information_en.pdf. Accessed 1 Jan 2020."},{"key":"7561_CR45","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012;30:2183\u20139.","journal-title":"J Clin Oncol"},{"key":"7561_CR46","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","volume":"128","author":"R Chen","year":"2016","unstructured":"Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128:1562\u20136.","journal-title":"Blood."},{"key":"7561_CR47","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/bjh.15539","volume":"183","author":"J Walewski","year":"2018","unstructured":"Walewski J, Hellmann A, Siritanaratkul N, Ozsan GH, Ozcan M, Chuncharunee S, et al. Prospective study of brentuximab vedotin in relapsed\/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy. Br J Haematol. 2018;183:400\u201310.","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"7561_CR48","doi-asserted-by":"crossref","first-page":"abstract 2923","DOI":"10.1182\/blood-2018-99-112235","volume":"132","author":"A Hagenbeek","year":"2018","unstructured":"Hagenbeek A, Zijlstra JM, Plattel WJ, Morschauser F, Lugtenburg PJ, Brice P, et al. Combining brentuximab vedotin with DHAP as salvage treatment in relapsed\/refractory Hodgkin lymphoma: the phase II HOVON\/LLPC transplant BRaVE study. Blood. 2018;132(Suppl 1):abstract 2923.","journal-title":"Blood"},{"key":"7561_CR49","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/annonc\/mdz009","volume":"30","author":"R Garcia-Sanz","year":"2019","unstructured":"Garcia-Sanz R, Sureda A, De La Cruz F, Canales M, Gonzalez AP, Pinana JL, et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO group). Ann Oncol. 2019;30:612\u201320.","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"7561_CR50","first-page":"abstract 2806","volume":"130","author":"RD Cassaday","year":"2017","unstructured":"Cassaday RD, Fromm JR, Cowan AJ, Smith SD, Libby EN, Philip M, et al. Radiographic and high-throughput sequencing (HTS)-based response assessment after brentuximab vedotin (BV) plus ifosfamide, carboplatin, and etoposide (ICE) for relapsed\/refractory (rel\/ref) classical Hodgkin lymphoma (cHL): updated results of a phase I\/II trial. Blood. 2017;130(Suppl 1):abstract 2806.","journal-title":"Blood"},{"issue":"Suppl 1","key":"7561_CR51","doi-asserted-by":"crossref","first-page":"abstract 132","DOI":"10.1182\/blood-2019-123925","volume":"134","author":"A Stamatoullas","year":"2019","unstructured":"Stamatoullas A, Ghesquieres H, Clement filliatre L, Quittet P, Morschhauser F, Ribrag V, et al. Brentuximab vedotin in first refractory\/relapsed classical Hodgkin lymphoma patients treated by chemotherapy (ICE) before autologous transplantation. Final analysis of phase II study. Blood. 2019;134(Suppl 1):abstract 132.","journal-title":"Blood"},{"key":"7561_CR52","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","volume":"21","author":"R Chen","year":"2015","unstructured":"Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT, et al. Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2015;21:2136\u201340.","journal-title":"Biol Blood Marrow Transplant"},{"key":"7561_CR53","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","volume":"132","author":"AS Lacasce","year":"2018","unstructured":"Lacasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132:40\u20138.","journal-title":"Blood."},{"key":"7561_CR54","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","volume":"131","author":"AF Herrera","year":"2018","unstructured":"Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131:1183\u201394.","journal-title":"Blood."},{"key":"7561_CR55","doi-asserted-by":"crossref","first-page":"5980","DOI":"10.1200\/JCO.2007.15.5887","volume":"26","author":"F Morschhauser","year":"2008","unstructured":"Morschhauser F, Brice P, Ferme C, Divine M, Salles G, Bouabdallah R, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse\/refractory Hodgkin\u2019s lymphoma: results of the prospective multicenter H96 trial by the GELA\/SFGM study group. J Clin Oncol. 2008;26:5980\u20137.","journal-title":"J Clin Oncol"},{"key":"7561_CR56","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3324\/haematol.2015.136408","volume":"101","author":"D Sibon","year":"2016","unstructured":"Sibon D, Morschhauser F, Resche-Rigon M, Ghez D, Dupuis J, Marcais A, et al. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA\/SFGM-TC study group. Haematologica. 2016;101:474\u201381.","journal-title":"Haematologica."},{"key":"7561_CR57","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.bbmt.2017.12.798","volume":"24","author":"EP Smith","year":"2018","unstructured":"Smith EP, Li H, Friedberg JW, Constine LS, Rimsza LM, Cook JR, et al. Tandem autologous hematopoietic cell transplantation for patients with primary progressive or recurrent Hodgkin lymphoma: a SWOG and blood and marrow transplant clinical trials network phase II trial (SWOG S0410\/BMT CTN 0703). Biol Blood Marrow Transplant. 2018;24:700\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"key":"7561_CR58","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/bjh.15184","volume":"181","author":"B Deau","year":"2018","unstructured":"Deau B, Amorim S, Perrot A, Quittet P, Cornillon J, Chaoui D, et al. Tandem haematopoietic stem cell transplantation for high risk relapsed\/refractory Hodgkin lymphoma: a LYSA study. Br J Haematol. 2018;181:341\u20139.","journal-title":"Br J Haematol"},{"key":"7561_CR59","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/01.HS9.0000564736.59814.ec","volume":"3","author":"L Bento","year":"2019","unstructured":"Bento L, Boumendil A, Fine H, Khvedelidze I, Blaise D, Fegueux N, et al. S1622 tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the LWP-EBMT. HemaSphere. 2019;3:749\u201350.","journal-title":"HemaSphere."},{"key":"7561_CR60","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mdx072","volume":"28","author":"PJ Brockelmann","year":"2017","unstructured":"Brockelmann PJ, Muller H, Casasnovas O, Hutchings M, Von Tresckow B, Jurgens M, et al. Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann Oncol. 2017;28:1352\u20138.","journal-title":"Ann Oncol"},{"key":"7561_CR61","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1200\/JCO.2012.47.1862","volume":"31","author":"R Pettengell","year":"2013","unstructured":"Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzner B, et al. Rituximab purging and\/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2013;31:1624\u201330.","journal-title":"J Clin Oncol"},{"key":"7561_CR62","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00277-016-2705-z","volume":"95","author":"J Bourcier","year":"2016","unstructured":"Bourcier J, Gastinne T, Leux C, Moreau A, Bossard C, Mahe B, et al. Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience. Ann Hematol. 2016;95:1287\u201393.","journal-title":"Ann Hematol"},{"key":"7561_CR63","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","volume":"377","author":"S Le Gouill","year":"2017","unstructured":"Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377:1250\u201360.","journal-title":"N Engl J Med"},{"issue":"22","key":"7561_CR64","doi-asserted-by":"crossref","first-page":"abstract 5357","DOI":"10.1182\/blood.V128.22.5357.5357","volume":"128","author":"A Chidiac","year":"2016","unstructured":"Chidiac A, Massoud R, Haidar M, Fares E, Bazabachi A, Cheikh JE. Post-transplant brentuximab maintenance appears more effective than post-transplant salvage brentuximab for relapsed\/refractory Hogkin\u2019s lymphoma. Blood. 2016;128(22):abstract 5357.","journal-title":"Blood"},{"key":"7561_CR65","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853\u201362.","journal-title":"Lancet."},{"issue":"Suppl 1","key":"7561_CR66","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1182\/blood-2018-99-118198","volume":"132","author":"M Hamadani","year":"2018","unstructured":"Hamadani M, Collins GP, Samaniego F, Spira AI, Davies A, Radford J, et al. Phase 1 study of Adct-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed\/refractory classical Hodgkin lymphoma. Blood. 2018;132(Suppl 1):928.","journal-title":"Blood."},{"key":"7561_CR67","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1080\/10428194.2016.1182164","volume":"58","author":"B Von Tresckow","year":"2017","unstructured":"Von Tresckow B, Morschhauser F, Szer J, Eichenauer DA, Abramson JS, Sureda A, et al. Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation. Leuk Lymphoma. 2017;58:222\u20135.","journal-title":"Leuk Lymphoma"},{"key":"7561_CR68","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018;36:1428\u201339.","journal-title":"J Clin Oncol"},{"key":"7561_CR69","volume-title":"(Opdivo) summary of product characteistics","author":"Bristol-Myers Squibb","year":"2015","unstructured":"Bristol-Myers Squibb. (Opdivo) summary of product characteistics. 2015. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/opdivo-epar-product-information_en.pdf. Accessed 1 Jan 2020."},{"key":"7561_CR70","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.2019000215","volume":"134","author":"P Armand","year":"2019","unstructured":"Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, et al. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019;134:22\u20139.","journal-title":"Blood."},{"key":"7561_CR71","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3109\/10428194.2012.744453","volume":"54","author":"SM Smith","year":"2013","unstructured":"Smith SM, Schoder H, Johnson JL, Jung SH, Bartlett NL, Cheson BD, et al. The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: cancer and Leukemia Group B 50602 (Alliance). Leuk Lymphoma. 2013;54:1405\u201310.","journal-title":"Leuk Lymphoma"},{"key":"7561_CR72","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/bjh.12630","volume":"164","author":"M Fanale","year":"2014","unstructured":"Fanale M, Assouline S, Kuruvilla J, Solal-Celigny P, Heo DS, Verhoef G, et al. Phase IA\/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. Br J Haematol. 2014;164:258\u201365.","journal-title":"Br J Haematol"},{"key":"7561_CR73","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","volume":"125","author":"A Rothe","year":"2015","unstructured":"Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, et al. A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;125:4024\u201331.","journal-title":"Blood."},{"key":"7561_CR74","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/hon.88_2629","volume":"37","author":"SM Ansell","year":"2019","unstructured":"Ansell SM, Bartlett NL, Chen RW, Herrera A, Domingo-Domenech E, Mehta A, et al. Investigating safety and preliminary efficacy of AFM13 plus pembrolizumab in patients with relapsed\/refractory Hodgkin lymphoma after brentuximab vedotin failure. Hematol Oncol. 2019;37:128.","journal-title":"Hematol Oncol"},{"key":"7561_CR75","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/hon.125_2629","volume":"37","author":"CA Ramos","year":"2019","unstructured":"Ramos CA, Torrano V, Bilgi M, Gerken C, Dakhova O, Mei Z, et al. CD30-chimeric antigen receptor (CAR) T cells for therapy of Hodgkin Lymphoma (HL). Hematol Oncol. 2019;37:119.","journal-title":"Hematol Oncol"},{"key":"7561_CR76","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.bbmt.2018.12.149","volume":"25","author":"NS Grover","year":"2019","unstructured":"Grover NS, Park SI, Ivanova A, Eldridge P, Mckay K, Cheng C, et al. A phase Ib\/II study of anti-CD30 chimeric antigen receptor T cells for relapsed\/refractory CD30+ lymphomas. Biol Blood Marrow Transplant. 2019;25:83.","journal-title":"Biol Blood Marrow Transplant"},{"key":"7561_CR77","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","volume":"23","author":"CM Wang","year":"2017","unstructured":"Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial. Clin Cancer Res. 2017;23:1156\u201366.","journal-title":"Clin Cancer Res"},{"key":"7561_CR78","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","volume":"32","author":"CM Bollard","year":"2014","unstructured":"Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014;32:798\u2013808.","journal-title":"J Clin Oncol"},{"key":"7561_CR79","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","volume":"116","author":"MR Green","year":"2010","unstructured":"Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268\u201377.","journal-title":"Blood"},{"key":"7561_CR80","unstructured":"Merck Sharp & Dohme B.V. (Keytruda) summary of product characteristics. 2015. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_en.pdf. Accessed 1 Jan 2020."},{"key":"7561_CR81","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","volume":"134","author":"R Chen","year":"2019","unstructured":"Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134:1144\u201353.","journal-title":"Blood."},{"key":"7561_CR82","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood.V89.2.403","volume":"89","author":"A Engert","year":"1997","unstructured":"Engert A, Diehl V, Schnell R, Radszuhn A, Hatwig MT, Drillich S, et al. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin\u2019s lymphoma. Blood. 1997;89:403\u201310.","journal-title":"Blood."},{"issue":"23","key":"7561_CR83","doi-asserted-by":"crossref","first-page":"abstract 3195","DOI":"10.1182\/blood.V126.23.3195.3195","volume":"126","author":"S Jauhari","year":"2015","unstructured":"Jauhari S, Plastaras J, Lukens J, Maity A, Schuster SJ, Nasta SD. Consolidative radiation therapy following autologous transplantation in relapsed or refractory Hodgkin lymphoma. Blood. 2015;126(23):abstract 3195.","journal-title":"Blood"},{"key":"7561_CR84","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijrobp.2017.05.007","volume":"99","author":"C Wilke","year":"2017","unstructured":"Wilke C, Cao Q, Dusenbery KE, Bachanova V, Lazaryan A, Lee CK, et al. Role of consolidative radiation therapy after autologous hematopoietic cell transplantation for the treatment of relapsed or refractory Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2017;99:94\u2013102.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7561_CR85","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1016\/j.ijrobp.2012.04.007","volume":"84","author":"JS Goda","year":"2012","unstructured":"Goda JS, Massey C, Kuruvilla J, Gospodarowicz MK, Wells W, Hodgson DC, et al. Role of salvage radiation therapy for patients with relapsed or refractory Hodgkin lymphoma who failed autologous stem cell transplant. Int J Radiat Oncol Biol Phys. 2012;84:e329\u201335.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7561_CR86","volume-title":"Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man - methodological consideration for using progression-free survival (PFS) or disease-free survival (DFS) in confirmatory trials. Revision 1","author":"European Medicines Agency","year":"2013","unstructured":"European Medicines Agency. Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man - methodological consideration for using progression-free survival (PFS) or disease-free survival (DFS) in confirmatory trials. Revision 1. 2013. https:\/\/www.ema.europa.eu\/en\/appendix-1-guideline-evaluation-anticancer-medicinal-products-man-methodological-consideration-using. Accessed 1 May 2019."},{"key":"7561_CR87","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/cncr.29082","volume":"121","author":"UA Matulonis","year":"2015","unstructured":"Matulonis UA, Oza AM, Ho TW, Ledermann JA. Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials. Cancer. 2015;121:1737\u201346.","journal-title":"Cancer."},{"key":"7561_CR88","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/apm.12926","volume":"127","author":"M Ehinger","year":"2019","unstructured":"Ehinger M, Pettersson L. Measurable residual disease testing for personalized treatment of acute myeloid leukemia. Apmis. 2019;127:337\u201351.","journal-title":"Apmis."},{"key":"7561_CR89","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.clml.2019.03.014","volume":"19","author":"S Molica","year":"2019","unstructured":"Molica S, Giannarelli D, Montserrat E. Minimal residual disease and survival outcomes in patients with chronic lymphocytic leukemia: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2019;19:423\u201330.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"7561_CR90","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/bjh.14996","volume":"180","author":"ML Chase","year":"2018","unstructured":"Chase ML, Armand P. Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions. Br J Haematol. 2018;180:177\u201388.","journal-title":"Br J Haematol"},{"key":"7561_CR91","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.seminhematol.2018.03.001","volume":"55","author":"O Landgren","year":"2018","unstructured":"Landgren O, Lu SX, Hultcrantz M. MRD testing in multiple myeloma: the main future driver for modern tailored treatment. Semin Hematol. 2018;55:44\u201350.","journal-title":"Semin Hematol"},{"key":"7561_CR92","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/bjh.13349","volume":"169","author":"Y Oki","year":"2015","unstructured":"Oki Y, Neelapu SS, Fanale M, Kwak LW, Fayad L, Rodriguez MA, et al. Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach. Br J Haematol. 2015;169:689\u201393.","journal-title":"Br J Haematol"},{"key":"7561_CR93","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3324\/haematol.2016.145102","volume":"101","author":"V Camus","year":"2016","unstructured":"Camus V, Stamatoullas A, Mareschal S, Viailly PJ, Sarafan-Vasseur N, Bohers E, et al. Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma. Haematologica. 2016;101:1094\u2013101.","journal-title":"Haematologica."},{"issue":"Suppl 5","key":"7561_CR94","first-page":"poster P060","volume":"101","author":"V Bachanova","year":"2016","unstructured":"Bachanova V, Carella A, Masszi T, Holowiecki J, Viviani S, Huebner D, et al. Evaluation of serum tarc levels in patients at risk of progression following autologous stem cell transplant for Hodgkin lymphoma: results from the AETHERA trial. Haematologica. 2016;101(Suppl 5):poster P060.","journal-title":"Haematologica"},{"key":"7561_CR95","first-page":"253","volume":"2019","author":"D Rossi","year":"1881","unstructured":"Rossi D, Condoluci A, Spina V, Gaidano G. Methods for measuring ctDNA in lymphomas. Methods Mol Biol. 1881;2019:253\u201365.","journal-title":"Methods Mol Biol"},{"key":"7561_CR96","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/annonc\/mdy476","volume":"30","author":"L Lenaerts","year":"2019","unstructured":"Lenaerts L, Vandenberghe P, Brison N, Che H, Neofytou M, Verheecke M, et al. Genomewide copy number alteration screening of circulating plasma DNA: potential for the detection of incipient tumors. Ann Oncol. 2019;30:85\u201395.","journal-title":"Ann Oncol"},{"key":"7561_CR97","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.3109\/10428194.2010.513749","volume":"51","author":"J Brandt","year":"2010","unstructured":"Brandt J, Dietrich S, Meissner J, Neben K, Ho AD, Witzens-Harig M. Quality of life of long-term survivors with Hodgkin lymphoma after high-dose chemotherapy, autologous stem cell transplantation, and conventional chemotherapy. Leuk Lymphoma. 2010;51:2012\u201320.","journal-title":"Leuk Lymphoma"},{"key":"7561_CR98","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/bjh.12038","volume":"159","author":"AY Minn","year":"2012","unstructured":"Minn AY, Riedel E, Halpern J, Johnston LJ, Horning SJ, Hoppe RT, et al. Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory\/relapsed Hodgkin lymphoma. Br J Haematol. 2012;159:329\u201339.","journal-title":"Br J Haematol"},{"key":"7561_CR99","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/bjh.14316","volume":"175","author":"SD Ramsey","year":"2016","unstructured":"Ramsey SD, Nademanee A, Masszi T, Holowiecki J, Abidi M, Chen A, et al. Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma. Br J Haematol. 2016;175:860\u20137.","journal-title":"Br J Haematol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07561-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-07561-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07561-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T17:05:12Z","timestamp":1605027912000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07561-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,10]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7561"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07561-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,10]]},"assertion":[{"value":"19 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AS reports research funding from Roche; personal financial interests in Takeda, Gilead, Celgene, Novartis, and Kite Gilead; and receipt of other payments from: Takeda, BMS, MSD, Roche, Celgene, Janssen, Novartis, Kite Gilead, Sanofi, Daiichi, and GenMab. MA reports research funding and other payments from Takeda. PB reports receipt of research funding from Takeda Oncology. MS reports research funding form Gilead and receipt of other payments from: Roche, Celgene, Kite Gilead, and Abbvie. CG reports no conflicts of interest. TV reports receipt of other payments from BMS, Genesis Pharmaceuticals, Roche, Takeda, Novartis, Gilead, Merck, Astellas, and Winmedica. PLZ reports receipt of other payments from: MSD, Verastem, Roche, Servier, Celgene, Novartis, Gilead, BMS, Portola, Morphosys, Janssen, Hikma and Celltrion. JW reports research funding from: Roche, GSK, Novartis, Takeda, Janssen; and receipt of other payments from Roche, Celgene, Takeda, Janssen, Servier, Amgen, BMS, Abbvie, Novartis, and Gilead.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1088"}}